Management TeamWe are a team of entrepreneurs spurred by the challenge of helping our
clients develop tomorrow’s medicines in a safer and faster way.
Dr Pierre Eftekhari
Chief Scientific Officer (CSO)
Dr Eftekhari is a life-science entrepreneur with a great depth of knowledge about the process of drug development. He holds a PhD in biology with a major in pharmacology from the Louis Pasteur University, Strasbourg. He has more than fifteen years’ combined academic and industrial experience of pharmacology.
Prior to founding Inoviem Scientific, Dr Eftekhari co-founded two other companies offering tailored drug development services. The partnerships he built with pharmaceutical companies and academic laboratories at international level have given him an in-depth understanding of the pharmaceutical industry’s needs. His considerable experience of the drug development process has given him the necessary determination to develop state-of-the-art technologies.
Dr Frédéric Perraud
Chief Financial Officer (CFO)
Dr Perraud is a life-science entrepreneur with over 10 years’ experience of biotech company management. He has a PhD in molecular biology and an MA from Louis Pasteur University, Strasbourg. Prior to joining Inoviem Scientific as CFO, Dr Perraud worked for 14 years as a researcher at Transgene, before moving to Carex, a drug development company operating in the field of metabolic diseases. He also had administrative positions as CFO, COO and CEO in a number of biotech companies (Neurofit, Carex and Polyplus Transfection)
Dr Daniel Da Costa
Communication and Commercial Officer (CCO)
Dr Da Costa graduated from the Ecole Normale Supérieure in Lyon and holds a PhD in molecular biology and a Master Innovation Management from the University of Strasbourg. Prior to joining Inoviem Scientific as CCO, he worked as research project manager in Glasgow, Portsmouth and Montreal, and as project manager at Semia, the Alsatian innovative business incubator, and medeuronet, a company dedicated to offering innovative services to the medtech industry.
Dr Rachel Amouroux
Head of Research
Dr Amouroux graduated from Université Pierre et Marie Curie (Paris VI) and from the Institut National des Sciences Appliquées (INSA) in Lyon where she obtained a Master in Biotechnologies. After being granted a PhD in Genetics for her work on DNA repair in collaboration with the Commissariat à l’Energie Atomique (CEA) and Paris VI, she spent 7 years as a research associate at Imperial College London, UK. Her academic track-record on epigenetics and DNA modifications has been acknowledged in top international peer-reviewed journals.